Max Healthcare Institute informed exchanges that its Board of Directors is scheduled to meet on May 21, 2026, to consider and approve the company’s standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The board will also consider recommending a final for FY26.
The company disclosed the development through a regulatory filing submitted to both the National Stock Exchange (NSE) and BSE on Thursday.
“We wish to inform that a meeting of the Board of Directors of the Company is scheduled to be held on Thursday, May 21, 2026, inter-alia, to:
consider and approve standalone and consolidated financial results of the Company for the quarter and financial year ended March 31, 2026 (“Financial Results”); and recommend final dividend, if any, on equity shares of the Company for the financial year ended March 31, 2026,” it said in the exchange filing.
also informed the exchanges that the trading window for dealing in the company’s securities will continue to remain closed for designated persons and their immediate relatives till 48 hours after the declaration of financial results.
Max Healthcare stock performance
While the stock has added 6% in the last 1 month, it has shed 4.5% in the past 6 months and 11% in the last 1 year. However, in 5 years, it has given multibagger returns, soaring 378%.
The had hit its 52-week high of ₹1,314.30 in July 2025 and 52-week low of ₹903.50 in April 2026.
Just in today’s deals, the stock added 1% to its day’s high of ₹1,060.
Max Healthcare Q3 Results
Max Healthcare Institute reported a mixed performance for the third quarter of FY26, as higher realisations and steady revenue growth supported earnings, while margins and operating metrics weakened on a sequential basis.
The company posted revenue of ₹2,484 crore in , up 9% from ₹2,281 crore in the corresponding quarter last year. EBITDA increased 5% year-on-year to ₹633 crore compared with ₹603 crore in Q3FY25, although EBITDA margin moderated to 25.5% from 26.4% a year ago.
Profit after tax stood at ₹344 crore, registering a 9% rise year-on-year, supported by improved realisations despite softer operating trends during the quarter.
On a quarter-on-quarter basis, however, performance softened. Revenue declined from ₹2,580 crore reported in the previous quarter, while EBITDA dropped from ₹694 crore. Net profit also fell sharply from ₹554 crore in Q2FY26, reflecting seasonal softness and temporary disruptions that weighed on overall operations.
Disclaimer: This story is for educational purposes only. Please consult with an investment advisor before making any investment decisions.